Aligos Therapeutics Inc. participated in the HEP-DART 2025 Meeting, held from December 7 to 11, 2025, in Honolulu, Hawaii. The company presented positive data from four studies, including two oral presentations. Highlights included new preclinical results demonstrating synergistic fat mass loss when ALG-055009 was combined with incretin receptor agonists, and updated clinical data on pevifoscorvir sodium for chronic hepatitis B virus infection. Early-stage research on antisense oligonucleotide therapies for HBV and HDV was also showcased. These presentations underscore Aligos's commitment to advancing therapies for liver and viral diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599355-en) on December 11, 2025, and is solely responsible for the information contained therein.